<< Back to News

System Formulary Update
Bezlotoxumab (Zinplava®)

Situation

Bezlotoxumab (Zinplava®) 25 mg/mL injection has been approved for addition to the UNC Health Medication Formulary.

Background

Bezlotoxumab is a human monoclonal antibody indicated to reduce recurrence of clostridioides difficile infection (CDI) in patients 18 years or older who are receiving antibacterial treatment for the treatment of CDI. Bezlotoxumab is dosed at 10 mg/kg and given as a 1-time intaravenous infusion; repeat dosing has not been evaluated. See the package insert for additional information.

It was reviewed by the System P&T Committee in January 2022 for formulary addition.

Assessment/Recommendations

The P&T Committee voted to APPROVE the addition of bezlotoxumab 25 mg/mL to System Formulary WITH RESTRICTION to outpatient/clinic encounters only (ie, no inpatient use).  

Formulary/Epic changes will Go-Live on Tuesday, March 22, 2022.